GFAP
A glial-specific type-III intermediate filament protein
References SySy GFAP antibodies
Wittnam JL, Portelius E, Zetterberg H, Gustavsson MK, Schilling S, Koch B, Demuth HU, Blennow K, Wirths O & Bayer TA (2012) Pyroglutamate A(beta) aggravates behavioral deficits in 5XFAD mice. Journal of Biological Chemistry Jan 20. [Epub ahead of print] Clone 134B1; IPHillmann A, Hahn S, Schilling S, Hoffmann T, Demuth HU, Bulic B, Schneider-Axmann T, Bayer TA, Weggen S & Wirths O (2011). No improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer's disease. Neurobiology of Aging, Sep 21. [Epub ahead of print]. rabbit antiserum; IHC
Hobohm C, Laignel F, Kacza J, Küppers-Tiedt L, Heindl M, Schneider D, Grosche J, Härtig W & Michalski D (2011). Long-lasting neuronal loss following experimental focal cerebral ischemia is not affected by combined administration of tissue plasminogen activator and hyperbaric oxygen. Brain Research 1417: 115-26. guinea pig antiserum; IHC
Ribic A, Flügge G, Schlumbohm C, Mätz-Rensing K, Walter L & Fuchs E (2011). Activity-dependent regulation of MHC class I expression in the developing primary visual cortex of the common marmoset monkey. Behavioral and Brain Functions 7: 1. rabbit antiserum; IHC
Wirths O, Erck C, Martens H, Harmeier A, Geumann C, Jawhar S, Kumar S, Multhaup G, Walter J, Ingelsson M, Degerman-Gunnarsson M, Kalimo H, Huitinga I, Lannfelt L & Bayer TA (2010). Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis. Journal of Biological Chemistry 285: 41517-24. rabbit antiserum; IHC
Ribic A, Zhang M, Schlumbohm C, Mätz-Rensing K, Uchanska-Ziegler B, Flügge G, Zhang W, Walter L & Fuchs E (2010). Neuronal MHC Class I Molecules are Involved in Excitatory Synaptic Transmission at the Hippocampal Mossy Fiber Synapses of Marmoset Monkeys. Cellular and Molecular Neurobiology 30: 827-39. rabbit antiserum; IHC
Christensen DZ, Schneider-Axmann T, Lucassen PJ, Bayer TA & Wirths O (2010). Accumulation of intraneuronal Abeta correlates with ApoE4 genotype. Acta Neuropathologica 119: 555-66. rabbit antiserum; IHC
General references GFAP
Triolo D, Dina G, Lorenzetti I, Malaguti M, Morana P, Del Carro U, Comi G, Messing A, Quattrini A & Previtali SC (2006). Loss of glial fibrillary acidic protein (GFAP) impairs Schwann cell proliferation and delays nerve regeneration after damage. Journal of Cell Science 119: 3981-93.Shiihara T, Sawaishi Y, Adachi M, Kato M & Hayasaka K (2004). Asymptomatic hereditary Alexander's disease caused by a novel mutation in GFAP. Journal of the Neurological Sciences 225: 125-7.
Eng LF, Ghirnikar RS & Lee YL (2000). Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000). Neurochemical Research 25: 1439-51. Review
Dyer CA, Kendler A, Jean-Guillaume D, Awatramani R, Lee A, Mason LM & Kamholz J (2000). GFAP-positive and myelin marker-positive glia in normal and pathologic environments. Journal of Neuroscience Research 60: 412-26.
Valentino KL, Jones EG & Kane SA (1983). Expression of GFAP immunoreactivity during development of long fiber tracts in the rat CNS. Brain Research 285: 317-36.
Palfreyman JW, Thomas DG, Ratcliffe JG & Graham DI (1979). Glial fibrillary acidic protein (GFAP): purification from human fibrillary astrocytoma, development and validation of a radioimmunoassay for GFAP-like immunoactivity. Journal of the Neurological Sciences 41: 101-13.
Jacque CM, Vinner C, Kujas M, Raoul M, Racadot J & Baumann NA (1978). Determination of glial fibrillary acidic protein (GFAP) in human brain tumors. Journal of the Neurological Sciences 35: 147-55.
